Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG3970 drug-drug interaction study with methotrexate and sulfasalazine in healthy adults
NL-OMON49569Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of GLPG3970 in chronic inflammatory conditions, rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), sponsored by Galapagos NV. Primary endpoints: Methotrexate maximum observed concentration, Methotrexate area under the curve and 7 more. Started Aug 2020; status: completed.
02
Drugs
GLPG3970
03
Conditions
chronic inflammatory conditionsrheumatoid arthritis (RA)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON49569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49569.